Inhibikase Therapeutics completed the acquisition of CorHepta Pharmaceuticals for $14.8m.

Synopsis

Inhibikase Therapeutics, a company specializing in kinase inhibitor therapeutics, completed the acquisition of CorHepta Pharmaceuticals, a company focused on cardiovascular therapies, for $14.8m.

Principals

target

Corhepta Pharmaceuticals

bidder

Inhibikase Therapeutics

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (3)

todd gluth

Partner at Cooley

Lawyer

bidder

Deals

£ 37.29 B

Total Value

scott mccall

Partner at Cooley

Lawyer

bidder

Deals

£ 74 M

Total Value

steve przesmicki

Partner at Cooley

Lawyer

bidder

Deals

£ 8.28 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy